All functions |
|
|---|---|
1–2*alpha confidence interval given point estimate, CV, and n |
|
1–2*alpha Fieller CI given point estimate, CV (, CVb) and n |
|
Helper functions |
|
Confidence limits of a CV for log-normal data |
|
CV from a given Confidence interval |
|
Decompose CV(T) and CV(R) from 'pooled' CV of T/R |
|
Pooled CV from several studies |
|
CVwR from the upper expanded limit (ABEL) |
|
Owen's Q-function |
|
Owen's Q-function via repeated integration by parts |
|
Owen's T-function |
|
Design matrices of period balanced incomplete block designs |
|
Sample Size Tables for the Classical 2x2 Crossover Design |
|
Sample Size Tables for the 2x2x3 Replicate Crossover Design |
|
Sample Size Tables for the 2x4x4 Replicate Crossover Design |
|
Sample Size Tables for the Parallel Group Design |
|
Removed functions in PowerTOST |
|
Deprecated functions in PowerTOST |
|
Expected power of the TOST procedure |
|
Expected power of the non-inferiority test |
|
Sample size based on expected power |
|
Sample size based on expected power for the non-inferiority test |
|
Show the 'known' designs |
|
Power analysis for average bioequivalence (ABE) |
|
Power analysis for scaled ABE for NTIDs |
|
Power analysis for scaled average bioequivalence (scABE) |
|
Power for two simultaneous TOST procedures |
|
(Empirical) Power for BE decision via FDA method for highly variable NTIDs |
|
(Empirical) Power for BE decision via FDA method for NTIDs |
|
(Empirical) Power for BE decision via linearized scaled ABE criterion |
|
(Empirical) Power of BE Decision via Reference Scaled ABE |
|
Power for equivalence of the ratio of two means with normality on original scale |
|
Power of the classical TOST procedure |
|
Power calculation of the BE decision with models incorporating groups |
|
Power of the TOST procedure obtained via simulations |
|
Power of dose-proportionality studies evaluated via Power model |
|
Power of the one-sided non-inferiority t-test |
|
(Empirical) Power of BE decision via scaled (widened) BE acceptance limits |
|
(Empirical) Power of BE decision via scaled (widened) BE acceptance limits |
|
p-value(s) of the TOST procedure |
|
Constructor of an object with class 'regSet' containing the regulatory settings for ABEL |
|
Sample size based on power of two TOSTs |
|
Sample size estimation for BE decision via FDA method for highly variable (HV) narrow therapeutic index drugs (NTIDs) |
|
Sample size estimation for BE decision via the FDA's method for narrow therapeutic index drugs (NTIDs) |
|
Sample size estimation for BE decision via linearized scaled ABE criterion |
|
Sample size estimation for BE Decision via Reference Scaled ABE |
|
Sample size for equivalence of the ratio of two means with normality on original scale |
|
Sample size based on power of TOST |
|
Sample size estimation of dose-proportionality studies evaluated via the power model |
|
Sample size for the non-inferiority t-test |
|
Sample size estimation for BE decision via scaled (expanded) BE acceptance limits |
|
Sample size estimation for ABEL and iteratively adjusted alpha |
|
Sample size estimation for BE decision via scaled (expanded) BE acceptance limits |
|
Scaled (widened) BE Acceptance Limits |
|
Iteratively adjusted alpha for ABEL |
|
Type I error rate for two simultaneous TOST procedures |
|